Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Prepaid Assets (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Prepaid Assets for 6 consecutive years, with $210566.0 as the latest value for Q3 2025.

  • On a quarterly basis, Prepaid Assets rose 87.63% to $210566.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $210566.0, a 87.63% increase, with the full-year FY2024 number at $81308.0, down 63.01% from a year prior.
  • Prepaid Assets was $210566.0 for Q3 2025 at Inhibikase Therapeutics, up from $138855.0 in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $1.5 million in Q4 2021 to a low of $81308.0 in Q4 2024.
  • A 5-year average of $655269.6 and a median of $543923.0 in 2023 define the central range for Prepaid Assets.
  • Peak YoY movement for Prepaid Assets: skyrocketed 2640.35% in 2021, then plummeted 80.33% in 2023.
  • Inhibikase Therapeutics' Prepaid Assets stood at $1.5 million in 2021, then fell by 25.63% to $1.1 million in 2022, then tumbled by 80.33% to $219817.0 in 2023, then crashed by 63.01% to $81308.0 in 2024, then skyrocketed by 158.97% to $210566.0 in 2025.
  • Per Business Quant, the three most recent readings for IKT's Prepaid Assets are $210566.0 (Q3 2025), $138855.0 (Q2 2025), and $931992.0 (Q1 2025).